Research Article |
Corresponding author: Naresh Podila ( nareshtrcp10@gmail.com ) Academic editor: Magdalena Kondeva-Burdina
© 2023 Naresh Podila, Mithun Rudrapal, Subramanyam Sibbala, Atul R. Bendale, Yanadaiah Palakurthi, Molakpogu Ravindra Babu, Kiran Manda, Renzon Daniel Cosme Pecho, Sreelatha Muddisett.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Podila N, Rudrapal M, Sibbala S, Bendale AR, Palakurthi Y, Babu MR, Manda K, Pecho RDC, Muddisett S (2023) In vitro antimitotic activity and in silico study of some 6-fluoro-triazolo-benzothiazole analogues. Pharmacia 70(4): 887-894. https://doi.org/10.3897/pharmacia.70.e109898
|
In this work, nine 6-fluoro-triazolo-benzothiazole derivatives were prepared and evaluated for in vitro antimitotic activity. In addition, in silico study was also done using tubulin protein (PDB: 6QQN) by molecular docking method. Results revealed that TZ2 and TZ9 were the most active compounds with antimitotic action opposing the standard drug, aspirin. Results of molecular docking exhibited the inhibitory potential of triazolo-benzothiazole against tubulin protein. The mitotic study indicates the efficacy of triazolo-benzothiazole analogues in inhibiting the proliferation of cancer cells either by promoting microtubule formation or affecting microtubules, thereby preventing microtubule breakdown.
Benzothiazole, 1,2,4-triazole, cancer, antimitotic activity, aspirin, mung beans
Cancer is a major cause of mortality globally, in both industrialized and developing nations (
Benzothiazole is an interesting moiety in medicinal chemistry that has been reported to exhibit anticancer, antitumor, antimicrobial, anticonvulsant, anti-diabetic, antitubercular, and antibacterial activity (
All the chemicals used were of synthetic grade. The melting point was determined by digital melting point apparatus. Thin-layer chromatography (TLC) was used to monitor the progress of reaction progress by using GF254 pre-coated aluminum plates (Merck), ethyl acetate: n-hexane (3:1) as the mobile phase, and ultra-violet (UV) chamber for visualization of spots. ELICIO FT-IR spectrometer was used to acquire the IR spectrum (
About 1.45 g (0.01 mole) of fluorochloro aniline and 8 gm (0.08 mole) of potassium thiocyanate were mixed with 20 mL of cold glacial acetic acid and 1.6 mL of bromine solution was added into it from a dropping funnel and agitated with a magnetic stirrer in an ice bath. The mixture was agitated for 10 hours at room temperature after adding the bromine solution. Overnight, an orange precipitate was formed at the bottom of the flask, it was then added with 6 mL of water and the mixture was promptly heated to 85 °C and filtered. The reaction mixture was cooled and neutralized which finally yielded a dark brown precipitate. After benzene re-crystallization and animal charcoal treatment, 2-amino-6-fluoro-7-chloro-(1,3)-benzothiazole was obtained as green precipitate (1 gm, 51.02%, melted at 210–212 °C) after drying in 80 °C in an oven.
To a 500 mL round bottom flask, 10 mL of concentrated HCl was added drop wise to 12 mL (0.02 mole) of hydrazine hydrate while stirring at 5–10 °C. After cooling the solution, 20.2 gm of 7-chloro-6-fluoro 2-amino benzothiazole was added, followed by 60 mL of ethylene glycol. The resulting mixture was refluxed for 3 hours processed by first letting the residue sink to the bottom of a beaker filled with crushed ice, then filtering, drying, and recrystallizing with ethanol.
About 2.19 gm of 7-chloro-6-fluoro-2-hydrazinyl-1,3-benzothiazole and 1 gm of potassium carbonate were added to 25 mL of formic acid in a 250 mL round bottom flask. The adduct was stabilized after two hours of refluxing in crushed ice. The residue was then purified and dried to obtain the pure product.
In a 500 mL of round bottom flask, 2.2 gm of 8-chloro-7-fluoro-1,9a-dihydrol [1,2,4] triazole (0.013 mole) was transferred in the presence of pyridine and 1.71 g of p-toluene sulphonamide, (0.02 mole) after which it was refluxed for two hours, poured onto pulverized ice, drained, final purified residue was obtained by recrystallization with ethanol.
In a 100 mL round bottom flask, 2.7 gm of 8-chloro-7-fluoro-1-[4-methylphenylsulphonyl-1,9a-dihydro [1,2,4] triazolo [3,4b] [1,3] benzothiazole was refluxed with equal quantities of primary and secondary aromatic amines for 2 hours in DMF. The mélange was chilled before being spread over pulverised ice. Using a sprinkle of activated charcoal, after alcohol and benzene separation, the material was filtered, dehydrated, and recrystallized from alcohol. The scheme of synthesis of 6-fluoro-triazolo-benzothiazole analogues is depicted in Fig.
6-fluoro-3-[(4-methylphenyl) sulfonyl]-N-(2-amino phenylamino)-3,3a-dihydro [1,2,4] triazolo [5,1-b][1,3] benzothiazol-5-amine (TZ1): Yield: 83%; white powder; mp: 112–114 °C; mf: C21H18FN5O2S2, mw: 455.52; Rf = 0.74 (EtOAc: n-But: CHCl3 2:1:1); FT-IR (KBr, cm-1): 1276.78, 1432.75, 1660, 1069, 1442, 1105, 1196; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 6.78–6.86 (m, 11H, Ar) 4.28 (s, 1H, NH2) 3.01 (m, 3H, CH3), 8.50 (s, 1H, NH); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.3, 59.5, 104.8, 110.2, 113.5, 117.2, 119.1, 119.7, 119.9, 122.8, 127.2, 127.8, 129.2, 129.4, 129.8, 133.2, 136.7, 138.4, 141.5, 149.1, 154.8; MS (m/z), M+: 455.50.
6-fluoro-3-[(4-methylphenyl)sulfonyl]-N-(4-hydroxypropanoic acid)-3,3a-dihydro [1,2,4] triazolo [5,1-b] [1,3] benzothiazol-5-amine (TZ2): Yield: 49%; Brown solid; mp: 118–122 °C; mf: C24H21FN4O5S2; mw: 528.57; Rf = 0.69 (EtOAc: n-Bu: CHCl3: 2:1:1); FT-IR (KBr, cm-1): 1348.45, 1527.14, 1598.48, 1127.34, 1398.72, 1164.64, 1118.53; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 6.21–6.92 (m, 10H, Ar) 9.38 (s, 1H, NH), 1.96 (m, 3H, CH3) 2.98 (s, 2H, CH2), 9.81, 13.10 (d, 2H, OH); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.8, 35.5, 60.8, 65.9, 67.4, 82.7, 103.7, 104.8, 113.6, 114.8, 115.3, 128.1, 129.4, 129.6, 129.8, 132.2, 133.4, 133.8, 136.5, 141.4, 143.2, 154.0, 155.6, 174.2 MS (m/z), M+: 528.24.
N-(carboxy phenyl amino)-6-fluoro-3-[(4-methyl phenyl) sulfonyl]-3,3a-dihydro [1,2,4] triazole [5,1-b] [1,3] benzothiazol-5-amine (TZ3): Yield: 72.8%; orange solid; mp: 161–163 °C; mf: C21H17FN4O3S2; mw: 456.41; Rf = 0.70 (CHCl3: n-Bu: EtOAc: 1:2:1); FT-IR (KBr, cm-1): 1298.21, 1521.57, 1614.57, 1152.86, 1487.45, 1019.26, 1224.26; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 7.16–7.23 (m, 8H, Ar), 9.38 (s, 1H, NH), 2.15 (m, 3H, CH3) 2.99 (s, 2H, CH2), 9.87, 11.82 (d, 2H, OH), 3.14 (s, 1H, NH); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.6, 60.2, 104.2, 110.5, 113.4, 116.2, 116.8, 120.2, 120.6, 127.2, 127.6, 129.1, 129.4, 129.7, 133.3. 136.5, 141.6, 148.2, 149.1, 154.3, 162.6; MS (m/z), M+: 456.15.
N-(4-methoxyphenylamino)-6-fluoro-3-[(4-methyl phenyl) sulfonyl]-3,3a-dihydro [1,2,4] triazolo [5,1-b] [1,3] benzothiazol-5-amine (TZ4): Yield: 48.6%; pink solid; mp: 186–188 °C; mf: C22H19FN4O3S2; mw: 470.53; Rf = 0.53 (CHCl3: n-But: EtOAc: 2:1:1); FT-IR (KBr, cm-1): 1311.85, 1538.47, 1597.41, 1123.82, 1476.14, 1083.53, 1191.68; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 7.12 -7.68 (m, 10H, Ar), 9.31 (s, 1H, NH), 3.01 (m, 3H, CH3), 2.92 (s, 2H, CH2), 3.27, 2.45 (s, 2H, CH2); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.2, 55.9, 60.4, 104.8, 110.3, 113.6, 115.2, 115.6, 120.1, 120.8, 127.2, 127.4, 129.3, 129.6, 129.9, 131.9, 133.6, 141.6, 149.5, 150.2, 152.4, 154.6; MS (m/z), M+: 470.25.
6-fluoro-3-[(4-methylphenyl)sulfonyl]-morphonyl-3,3a-dihydro [1,2,4] triazolo [5,1-b] [1,3] benzothiazol-5-amine (TZ5): Yield: 63.14%, milkfish; mp: 168–172 °C; mf: C19H20FN5O3S2; mw: 449.51; Rf = 0.82 (EtOAc:n-Bu1: CHCl3: 2:1:1); FT-IR (KBr, cm-1): 1198.57, 1457.01, 1668.27, 1125.65, 1502.48, 1183.34, 1210.01; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 7.15–7.83 (m, 5H, Ar), 1.98 (m, 3H, CH3) 3.18 (s, 2H, CH2), 3.01–3.47 (m, 4H, CH2); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.6, 41.7, 56.1, 56.3, 60.4, 64.2, 64.5, 104.5, 105.7, 113.4, 127.2, 127.7, 128.4, 129.4, 129.9, 132.6, 136.6, 141.8, 143.2; MS (m/z), M+: 449.32.
6-fluoro-(4-pyrrolidinyl)-3-[(4-methylphenyl)sulphonyl]-3,3a-dihydro [1,2,4]triazolo [5,1-b] [1,3] benzthiazol-5-amine (TZ6): Yield: 51.5%; cream; mp: 176–178 °C; mf: C19H19FN4O2S2; mw: 418.50; Rf = 0.87 (EtOAc: n-But:CHCl3 2:1:1); FT-IR (KBr, cm-1): 1301.20, 1558.51, 1637.68, 1084.45, 1493.29, 1137.87, 1204.60; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 6.78–6.85 (m, 6H, Ar), 3.00 (m, 3H, CH3) 1.99 (m, 2H, CH2), 2.96–3.47 (m, 4H, CH2); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.6, 25.2, 25.5, 51.2, 51.8, 60.4, 104.7, 104.8, 105.4, 112.3, 126.3, 126.9, 127.8, 129.3, 129.8, 132.5, 136.2, 140.5, 142.4; MS (m/z), M+: 418.27.
6-fluoro-N-diethylamino-3-[(4-methylphenyl)sulfonyl]-3,3a-dihydro [1,2,4] triazolo [5,1-b] [1,3] benzothiazol-5-amine (TZ7): Yield: 63.7%, blue; mp: 110–112 °C; mf: C19H21FN4O2S2; mw: 420.52; Rf = 0.52 (EtOAc : n-But: CHCl3 2:1:1); FT-IR (KBr, cm-1): 1310.21, 1522.57, 1685.01, 1107.27, 1524.84, 1098.21, 1267.47; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 7.04 -7.34 (m, 5H, Ar), 2.04 - 3.64 (m, 6H, CH3) 2.97 (m, 4H, CH2); 13C-NMR (CDCl3, 100 MHz) d ppm: 24.15, 43.1, 52.3, 54.8, 61.2, 64.8, 64.9, 101.3, 104.3, 112.6, 123.4, 127.4, 128.3, 128.7, 129.4, 131.2, 133.8, 141.8, 144.9; MS (m/z), M+: 420.12.
1-[6-fluoro-7-(4-phenethyl amino)-3-[4-methyl phenyl] sulphonyl]-3,3a dihydro [1, 2, 4] triazole [5,1-b] [1,3] benzothiazole (TZ8): Yield: 57.9%; green; mp: 116–119 °C; mf: C23H21FN4O2S2; mw: 468.56; Rf = 0.72 (EtOAc: n-Bu1: CHCl3: 2:1:1); FT-IR (KBr, cm-1): 1317.34, 1503.04, 1621.27, 1089.57, 1457.14, 1200.62, 1243.18; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 7.07–7.64 (m, 11H, Ar), 3.05–3.83 (m, 4H, CH2) 7.68 (s, H, NH) 3.08 (m, 3H, CH3); 13C-NMR (CDCl3, 100 MHz) d ppm: 23.4, 25.3, 44.8, 53.6, 60.8, 62.7, 69.4, 103.5, 106.7, 110.2, 114.6, 124.6, 127.6, 128.9, 129.1, 129.6, 129.8, 130.4, 132.7, 134.8, 1412.3, 144.6, 148.3; MS (m/z), M+: 468.25.
6-fluoro-3-[(4-methyl phenyl) sulfonyl]-5-(naphthyl amino)-3,3a-dihydro[1,2,4] triazolo [5,1- b] [1,3] Benzothiazole (TZ9): Yield:63.78%; violet; mp: 155–158 °C; mf: C25H19FN4O2S2; mw: 490.57; Rf = 0.91 (EtOAc: n-Bul:CHCl3: 2:1:1); FT-IR (KBr, cm-1): 1314.47, 1582.17, 1605.23, 1041.89, 1487.24, 1317.27, 1151.07; 1H-NMR (DMSO-d6, 300 MHz) d ppm: 7.13–7.82 (m, 6H, aromatic), 3.14–3.57 (m, 4H, CH2) 9.27 (s, 4H, NH) 2.37 (m, 3H, CH3); 13C-NMR (CDCl3, 100 MHz) d ppm: 21.3, 23.5, 26.4, 27.6, 40.6, 45.7, 61.2, 64.3, 84.5, 102.3, 108.4, 110.8, 116.2, 125.3, 126.4, 126.8, 128.6, 128.9, 129.5, 130.2, 130.6, 130.9, 131.2, 133.4, 1491.57; MS (m/z), M+: 490.30.
The antimitotic activity was evaluated according to a previously reported method (
Molecular docking was performed on PyRx 0.8 platform (
Fig.
Anti-mitotic activity was tested for all the compounds (TZ1–TZ9) (Table
Sl. No. | Compound code | Name of drug and concentration | Initial weight (gms) | Weight at | Drain radical length | No. of seeds germinated | % seeds germinated | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
To (gm) | T48 (gm) | To(cm) | T48 (cm) | To | T48 | To | T48 | ||||
1 | TZ1 | 1 mg | 1.52 | 2.63 | 3.89 | 1.29 | 1.38 | 9 | 11 | 50% | 60% |
3 mg | 1.54 | 3.17 | 4.21 | 1.19 | 1.30 | 12 | 14 | 55% | 65% | ||
2. | TZ2 | 1 mg | 1.56 | 3.21 | 4.52 | 1.12 | 1.25 | 11 | 12 | 50% | 65% |
3 mg | 1.54 | 3.52 | 4.12 | 0.81 | 1.06 | 12 | 13 | 55% | 60% | ||
3. | TZ3 | 1 mg | 1.52 | 3.12 | 4.21 | 1.00 | 1.12 | 7 | 9 | 35% | 45% |
3 mg | 1.54 | 2.25 | 3.74 | 0.89 | 1.21 | 9 | 11 | 40% | 45% | ||
4. | TZ4 | 1 mg | 1.54 | 3.09 | 3.99 | 0.78 | 0.84 | 9 | 11 | 50% | 60% |
3 mg | 1.55 | 3.13 | 3.89 | 0.52 | 0.72 | 10 | 12 | 55% | 65% | ||
5. | TZ5 | 1 mg | 1.55 | 3.48 | 3.85 | 0.69 | 0.89 | 9 | 10 | 50% | 65% |
3 mg | 1.56 | 3.24 | 3.98 | 0.71 | 0.74 | 10 | 11 | 55% | 60% | ||
6. | TZ6 | 1 mg | 1.54 | 2.48 | 3.61 | 0.72 | 0.79 | 9 | 10 | 50% | 55% |
3 mg | 1.52 | 3.04 | 3.94 | 0.74 | 0.82 | 10 | 11 | 40% | 55% | ||
7. | TZ7 | 1 mg | 1.55 | 3.34 | 4.18 | 0.89 | 1.14 | 9 | 10 | 40% | 50% |
3 mg | 1.54 | 3.42 | 3.99 | 0.86 | 0.83 | 10 | 11 | 40% | 55% | ||
8. | TZ8 | 1 mg | 1.52 | 3.45 | 3.75 | 0.89 | 0.86 | 8 | 10 | 45% | 55% |
3 mg | 1.55 | 3.51 | 3.81 | 0.85 | 0.94 | 9 | 11 | 40% | 55% | ||
9. | TZ9 | 1 mg | 1.52 | 2.73 | 3.93 | 1.32 | 1.45 | 10 | 12 | 50% | 60% |
3 mg | 1.54 | 3.07 | 4.02 | 1.25 | 1.32 | 11 | 13 | 55% | 65% | ||
10. | Standard Aspirin | 1 mg | 1.56 | 3.64 | 4.32 | 0.52 | 0.58 | 7 | 9 | 35% | 45% |
3 mg | 1.54 | 3.42 | 4.12 | 0.58 | 0.62 | 6 | 8 | 30% | 40% | ||
11. | Control | 1.56 | 3.52 | 4.32 | 1.05 | 0.98 | 9 | 11 | 45% | 55% |
The three-dimensional structure of tubulin and guanosine triphosphate (PDB: 6QQN) was used in the study. Prior to docking active site amino acid residues were identified. The following amino acids viz., Gln146, Thr145, Gln11, Ser178, Ala180, Asn101, Asp98, Glu71, Ser140, Gln144, Gln143, Ala100, ASP69, Tyr224, Ser140, and Ala99 are present in the catalytic pocket of the protein molecule, as shown in Fig.
PyRx calculated binding energies of protein-ligand complexes. The protein-ligand interaction is a measure of binding affinity. The binding affinity of TZ9 (-10.9 kcal/mol) was the highest among the selected molecules whose binding energy was greater than that of standard aspirin (-6.5 kcal/mol) and co-crystal ligand (guanosine triphosphate) (-8.2 kcal/mol). Table
In this work, nine 6- fluoro-triazolo-benzothiazole derivatives were prepared and evaluated for in vitro antimitotic activity. In addition, in silico study was also done using tubulin protein (PDB: 6QQN) by molecular docking method. The antimitotic study indicates the efficacy of triazolo-benzothiazole analogues in inhibiting the proliferation of cancer cells either by promoting microtubule formation or affecting microtubules, thereby preventing microtubule breakdown.
The authors declare no conflict of interest.